Objective: Spathiphyllum wallisii has a rich history in traditional medicine, notably for its anti-inflammatory and anti-cancer properties. Given the pivotal role of growth factors and their receptors in cancer initiation and progression, exploring the potential of Spathiphyllum wallisii phytochemicals as cancer therapeutics targeting these receptors is essential. Methods: This study employs an in-silico approach to investigate the cancer therapeutic potential of Spathiphyllum wallisii phytochemicals against growth factor receptors. Molecular docking simulations using PyRx were conducted to predict the binding affinity between the phytochemicals and the receptors. Results: Eight phytocompounds sourced from Spathiphyllum wallisii were initially screened based on their binding affinity towards growth factor receptors. Ligands exhibiting strong binding with GFR targets, with a binding score of less than -8.5 kcal/mol, were selected for further investigation. Among these, rotenone displayed notable binding affinity to the receptors, suggesting its potential as a targeted cancer therapy. These findings lay the groundwork for future in-vitro and in-vivo experiments to validate the efficacy of these phytochemicals as cancer treatments.